AbbVie’s telisotuzumab adizutecan achieved an ORR of 63% in EGFR-mutant NSCLC patients, with current ADC options in this ...

$1.5 million is the 'magic number' for retirement savings—here's how long it lasts in every U.S. state ...

An AbbVie drug gives patients a new choice as the ... Approval of the drug, telisotuzumab vedotin, brand name Emrelis, covers the treatment of non-squamous NSCLC that is locally advanced or ...

AbbVie ABBV announced that the FDA has granted ... The drug will be marketed under the brand name Emrelis. Under this approval, Emrelis is approved to treat adult patients with locally advanced ...

Before his stint at AbbVie, Gandor spent more than a decade at Takeda ... “We can’t have this world where we continue to have one brand-centric campaign that we think is going to apply to everybody,” ...

Put your money to work and make it make you money. Unfortunately, it’s not going to make you much money in a standard ...

Millions of Americans face the difficult decision of choosing between their health and their finances. Prescription ...

AbbVie is hoping to extend its range of neurotoxin-based pharma and cosmetic products with trenibotulinumtoxinE (TrenibotE), a short-acting successor to its blockbuster Botox brand, that has just ...

Whether they’re suffering from red, itchy eyes during allergy season, dealing with the discomfort of ear wax buildup or ...

The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research reports on 16 major stocks, including Berkshire Hathaway Inc. (BRK.B), ...

The long-term accommodations sector shows promise for stable growth amid rockier economic times, Choice’s CEO shared during a ...

Thwarted in her ambition to become a brewmaster, Kiran Mazumdar-Shaw channeled her frustrations into building a knockoff drug ...